Nat Mulkey, MD, Carl G. Streed Jr, MD, MPH, and Barbara M. Chubak, MD
Some clinicians cite absence of long-term data to justify not fully deferring surgery for children with DSD, and legal restrictions of early procedures are also at play.
AMA J Ethics. 2021; 23(7):E550-556. doi:
10.1001/amajethics.2021.550.
Dr Nat Mulkey and Dr Carl G. Streed Jr join Ethics Talk to discuss their article coauthored with Dr Barbara M. Chubak, "A Call to Update Standard of Care for Children With Differences in Sex Development."
A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021; 23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021; 23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Pringl Miller, MD, Preeti R. John, MD, MPH, and Sabha Ganai, MD, PhD, MPH
A surgeon’s duty is to identify goals of care, including those about quality of life, from a patient’s perspective and to consider how to achieve them.
AMA J Ethics. 2021; 23(10):E778-782. doi:
10.1001/amajethics.2021.778.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Patients can now easily view their health records, so clinicians must consider a reader’s interpretation of how they convey sensitive personal health information. What might this mean for ethics consultants?
AMA J Ethics. 2020; 22(9):E784-791. doi:
10.1001/amajethics.2020.784.